Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed May 6, 2025 · 10-Q · 36 days after period end · 0000950170-25-064412
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $611.52M | $359.48M | $231.50M | $188.83M |
| Net Income | -$447.51M | $36.12M | -$516.76M | -$105.03M |
| EPS Diluted | -$4.60 | $0.37 | -$5.86 | -$1.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 6, 2025 · 36 d after period end
